Literature DB >> 10961721

Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity.

R J Andrade1, M I Lucena, J Aguilar, M D Lazo, R Camargo, P Moreno, M D García-Escaño, A Marquez, R Alcántara, G Alcáin.   

Abstract

Liver injury induced by benzodiazepines is rare and is classified as an unpredictable or idiosyncratic hepatotoxic reaction. Early reports indicated that in most cases the pattern of liver injury was cholestatic. We describe three patients with persistent increases in liver transaminase levels after several weeks of treatment with bentazepam, a benzodiazepine marketed in Spain for anxiety disorders. In all cases withdrawal of the drug was followed by resolution of transaminase level abnormalities. A liver biopsy (done in one patient only) showed histological evidence of severe chronic active hepatitis. In conclusion, these findings, together with two previously published case reports, suggest that a benzodiazepine can cause chronic hepatitis and argue in favor of using liver function tests to monitor all patients taking bentazepam.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961721     DOI: 10.1023/a:1005520523502

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  3 in total

Review 1.  Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists.

Authors:  Raúl-J Andrade; Mercedes Robles; Alejandra Fernández-Castañer; Susana López-Ortega; M-Carmen López-Vega; M-Isabel Lucena
Journal:  World J Gastroenterol       Date:  2007-01-21       Impact factor: 5.742

Review 2.  Practical guidelines for diagnosis and early management of drug-induced liver injury.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

Review 3.  'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports.

Authors:  Laura Orsolini; John M Corkery; Stefania Chiappini; Amira Guirguis; Alessandro Vento; Domenico De Berardis; Duccio Papanti; Fabrizio Schifano
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.